{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T07:22:50Z","timestamp":1794295370148,"version":"4.9.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Karolinska Institute","id":[{"id":"https:\/\/ror.org\/056d84691","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Gastrin-releasing peptide receptor (GRPR) is overexpressed in several malignant tumours, while its physiological expression in major organs, except for pancreas, is low. GRPR is therefore an interesting target in nuclear medicine. The GRPR-binding ligand, [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-NOTA-PEG\n                      <jats:sub>2<\/jats:sub>\n                      -RM26 has previously been proven safe in humans. This study evaluates human dosimetry of the radioligand using 12 cancer patients (6 women with breast cancer and 6 men with prostate cancer) based on PET-CT imaging at six timepoints post injection. The voided urine was also collected to serve as an input to a urinary bladder model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The pancreas, liver, spleen, kidney parenchyma, gall bladder, urinary bladder contents and cortical bone were identified as source organs\/regions. Results using OLINDA\/EXM 2.3.0 dosimetry software showed that the urinary bladder wall was the organ that received the highest absorbed dose, 197\u2009\u00b1\u200949 \u00b5Gy\/MBq, followed by the pancreas, 111\u2009\u00b1\u200942 \u00b5Gy\/MBq, and the kidneys, 32\u2009\u00b1\u200910 \u00b5Gy\/MBq. The osteogenic cells received 18\u2009\u00b1\u20095 \u00b5Gy\/MBq. The median (range) of the total excreted activity through urine was 56% (43\u201375%) of the injected activity in 4h. The effective dose (ICRP 103) from an injection of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga -NOTA-PEG\n                      <jats:sub>2<\/jats:sub>\n                      -RM26 was calculated to 19 \u00b5Sv\/MBq, using a 1h voiding interval in the urinary bladder model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      A standard person of 70kg receiving 140MBq of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-NOTA-PEG\n                      <jats:sub>2<\/jats:sub>\n                      -RM26 will receive an effective dose of 2.6 mSv, which is lower or in accordance with other\n                      <jats:sup>68<\/jats:sup>\n                      Ga-labelled GRPR targeted radioligands.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Clinicaltrials.gov, NCT06147362, Registered 17 November 2023 \u2013 Retrospectively registered,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT06147362\" ext-link-type=\"uri\">https:\/\/www.clinicaltrials.gov\/study\/NCT06147362<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-026-01472-2","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:45:29Z","timestamp":1781743529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-in-human radiation dosimetry of the GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in patients with prostate and breast cancer"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0442-7625","authenticated-orcid":false,"given":"Annie","family":"Bj\u00e4reback","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Estenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Tzortzakakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimma","family":"Axelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunde","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske","family":"Altena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy A.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Hindorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"6","key":"1472_CR1","doi-asserted-by":"publisher","first-page":"792","DOI":"10.2967\/jnumed.119.234971","volume":"61","author":"L Baratto","year":"2020","unstructured":"Baratto L, Duan H, M\u00e4cke H, Iagaru A. Imaging the distribution of gastrin-releasing peptide receptors in cancer. J Nucl Med. 2020;61(6):792\u20138.","journal-title":"J Nucl Med"},{"issue":"1","key":"1472_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/MED.0b013e328340ff93","volume":"18","author":"ID Majumdar","year":"2011","unstructured":"Majumdar ID, Weber HC. Biology of mammalian bombesin-like peptides and their receptors. Curr Opin Endocrinol Diabetes Obes. 2011;18(1):68\u201374.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"1472_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ygeno.2004.01.008","volume":"84","author":"H Sano","year":"2004","unstructured":"Sano H, Feighner SD, Hreniuk DL, Iwaasa H, Sailer AW, Pan J, et al. Characterization of the bombesin-like peptide receptor family in primates. Genomics. 2004;84(1):139\u201346.","journal-title":"Genomics"},{"issue":"1","key":"1472_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13550-024-01116-3","volume":"14","author":"L Xiao","year":"2024","unstructured":"Xiao L, Fang Z, Tang Y, Sun Y, Zhu Z, Li J, et al. Evaluation of gastrin-releasing peptide receptor, prostate-specific membrane antigen, and neurotensin receptor 1 as potential biomarkers for accurate prostate cancer stratified diagnosis. EJNMMI Res. 2024;14(1):55.","journal-title":"EJNMMI Res"},{"issue":"8","key":"1472_CR5","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.2967\/jnumed.124.269444","volume":"66","author":"C Morgat","year":"2025","unstructured":"Morgat C, Duan H, Dalm S, Hindi\u00e9 E, G\u00fcnther T, Krause BJ, et al. A Vision for gastrin-releasing peptide receptor targeting for imaging and therapy: perspective from academia and industry. J Nucl Med. 2025;66(8):1160\u20137.","journal-title":"J Nucl Med"},{"issue":"1","key":"1472_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.5858\/arpa.2012-0679-OA","volume":"138","author":"J Mattei","year":"2014","unstructured":"Mattei J, Achcar RD, Cano CH, Macedo BR, Meurer L, Batlle BS, et al. Gastrin-releasing peptide receptor expression in lung cancer. Arch Pathol Lab Med. 2014;138(1):98\u2013104.","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"1472_CR7","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/ph16050674","volume":"16","author":"BA Nock","year":"2023","unstructured":"Nock BA, Kanellopoulos P, Joosten L, Mansi R, Maina T. Peptide radioligands in cancer theranostics: agonists and antagonists. Pharmaceuticals (Basel). 2023;16(5):674.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"22","key":"1472_CR8","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.3390\/cancers13225766","volume":"13","author":"R Mansi","year":"2021","unstructured":"Mansi R, Nock BA, Dalm SU, Busstra MB, van Weerden WM, Maina T. Radiolabeled bombesin analogs. Cancers (Basel). 2021;13(22):5766.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1472_CR9","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2967\/jnumed.112.114082","volume":"54","author":"A Roivainen","year":"2013","unstructured":"Roivainen A, K\u00e4hk\u00f6nen E, Luoto P, Borkowski S, Hofmann B, Jambor I, et al. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86\u20137548 in healthy men. J Nucl Med. 2013;54(6):867\u201372.","journal-title":"J Nucl Med"},{"issue":"11","key":"1472_CR10","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.2967\/jnumed.120.258814","volume":"62","author":"IL Bakker","year":"2021","unstructured":"Bakker IL, Fr\u00f6berg AC, Busstra MB, Verzijlbergen JF, Konijnenberg M, van Leenders G, et al. GRPr Antagonist (68)Ga-SB3 PET\/CT imaging of primary prostate Cancer in therapy-na\u00efve patients. J Nucl Med. 2021;62(11):1517\u201323.","journal-title":"J Nucl Med"},{"issue":"1","key":"1472_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13550-018-0462-9","volume":"8","author":"S Gnesin","year":"2018","unstructured":"Gnesin S, Cicone F, Mitsakis P, Van der Gucht A, Baechler S, Miralbell R, et al. First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist (68)Ga-NODAGA-MJ9. EJNMMI Res. 2018;8(1):108.","journal-title":"EJNMMI Res"},{"issue":"12","key":"1472_CR12","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.2967\/jnumed.119.238808","volume":"61","author":"L Gruber","year":"2020","unstructured":"Gruber L, Jim\u00e9nez-Franco LD, Decristoforo C, Uprimny C, Glatting G, Hohenberger P, et al. MITIGATE-NeoBOMB1, a Phase I\/IIa study to evaluate safety, pharmacokinetics, and preliminary imaging of (68)Ga-NeoBOMB1, a gastrin-releasing peptide receptor antagonist. GIST Patients J Nucl Med. 2020;61(12):1749\u201355.","journal-title":"GIST Patients J Nucl Med"},{"issue":"6","key":"1472_CR13","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2967\/jnumed.117.198929","volume":"59","author":"J Zhang","year":"2018","unstructured":"Zhang J, Niu G, Fan X, Lang L, Hou G, Chen L, et al. PET using a grpr antagonist (68)Ga-RM26 in healthy volunteers and prostate Cancer patients. J Nucl Med. 2018;59(6):922\u20138.","journal-title":"J Nucl Med"},{"issue":"1","key":"1472_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13550-025-01204-y","volume":"15","author":"A Bj\u00e4reback","year":"2025","unstructured":"Bj\u00e4reback A, Jonmarker O, Tzortzakakis A, Jussing E, Li C, Altena R, et al. First-in-human experience with GRPR antagonist [(68)Ga]Ga-NOTA-PEG(2)-RM26 in prostate and breast cancer patients using PET\/CT. EJNMMI Res. 2025;15(1):12.","journal-title":"EJNMMI Res"},{"key":"1472_CR15","unstructured":"ICRP. The 2007 Recommendations of the international commission on radiological protection. ICRP Publication. 2007;103."},{"issue":"5","key":"1472_CR16","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s00259-024-06640-x","volume":"51","author":"C Stokke","year":"2024","unstructured":"Stokke C, Gnesin S, Tran-Gia J, Cicone F, Holm S, Cremonesi M, et al. EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials. Eur J Nucl Med Mol Imaging. 2024;51(5):1268\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1472_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry\u2013standardization of nomenclature. J Nucl Med. 2009;50(3):477\u201384.","journal-title":"J Nucl Med."},{"key":"1472_CR18","doi-asserted-by":"publisher","first-page":"S197","DOI":"10.1016\/S0969-8051(22)00408-5","volume":"108\u2013109","author":"E Jussing","year":"2022","unstructured":"Jussing E, Moein MM, Tegnebratt T, Semetaite V, Liepins E, Tzortzakakis A, et al. P-271 - Preparation and cGMP-compliant production of the bombesin analogue [68Ga]Ga-NOTA-RM26 for first-in-human clinical study of gastrin-releasing peptide receptor expression in prostate Cancer. Nucl Med Biol. 2022;108\u2013109:S197\u20138.","journal-title":"Nucl Med Biol"},{"issue":"4","key":"1472_CR19","first-page":"102s","volume":"40","author":"SR Thomas","year":"1999","unstructured":"Thomas SR, Stabin MG, Chen CT, Samaratunga RC. MIRD pamphlet No. 14 revised: a dynamic urinary bladder model for radiation dose calculations. task group of the mird committee, society of nuclear medicine. J Nucl Med. 1999;40(4):102s-s123.","journal-title":"J Nucl Med."},{"key":"1472_CR20","doi-asserted-by":"crossref","unstructured":"ICRP. Basic anatomical & physiological data for use in radiological protection - The Skeleton. ICRP Publication 70. Annals of the ICRP. 1995;25.","DOI":"10.1016\/S0146-6453(00)80004-4"},{"issue":"3\u20134","key":"1472_CR21","first-page":"5","volume":"32","author":"Basic anatomical and","year":"2002","unstructured":"Basic anatomical and. physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRPPublication 89. Ann ICRP. 2002;32(3\u20134):5\u2013265. PMID:14506981.","journal-title":"Ann ICRP"},{"key":"1472_CR22","unstructured":"Becquerel LNH. Table de Radionucleides. 1998."},{"issue":"9","key":"1472_CR23","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2967\/jnumed.115.157123","volume":"56","author":"SJ Chittenden","year":"2015","unstructured":"Chittenden SJ, Hindorf C, Parker CC, Lewington VJ, Pratt BE, Johnson B, et al. A Phase 1, Open-label study of the biodistribution, pharmacokinetics, and dosimetry of 223Ra-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases. J Nucl Med. 2015;56(9):1304\u20139.","journal-title":"J Nucl Med"},{"issue":"1","key":"1472_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40658-018-0239-2","volume":"6","author":"K Sandgren","year":"2019","unstructured":"Sandgren K, Johansson L, Axelsson J, Jonsson J, \u00d6gren M, \u00d6gren M, et al. Radiation dosimetry of [(68)Ga]PSMA-11 in low-risk prostate cancer patients. EJNMMI Phys. 2019;6(1):2.","journal-title":"EJNMMI Phys"},{"issue":"6","key":"1472_CR25","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2967\/jnumed.112.114165","volume":"54","author":"RC Walker","year":"2013","unstructured":"Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M. Measured human dosimetry of 68Ga-dotatate. J Nucl Med. 2013;54(6):855\u201360.","journal-title":"J Nucl Med"},{"key":"1472_CR26","doi-asserted-by":"crossref","unstructured":"ICRP. Radiation dose to patients from radiopharmaceuticals - Addendum 3 to ICRP publication 53, ICRP publication 106. Ann ICRP. 2008;38:(1\u20132).","DOI":"10.1016\/j.icrp.2008.09.002"}],"updated-by":[{"DOI":"10.1186\/s13550-026-01541-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T00:00:00Z","timestamp":1794182400000}}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01472-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01472-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01472-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:35:11Z","timestamp":1794292511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01472-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1472"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01472-2","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13550-026-01541-6","URL":"https:\/\/doi.org\/10.1186\/s13550-026-01541-6","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Swedish Ethical Review Authority and the Swedish Medical Products Agency (Dnr: 2021\u201306886-01, EudraCT: 2021\u2013004980-28). Written informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data presented has been approved for publication, each patient has provided written informed consent.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"96"}}